Moss, 14 December 2022
Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, has appointed Dr Aleksandra Havelka as its new Chief Scientific Officer (CSO). Dr Havelka comes from the role as VP Science and Clinical Affairs at Gentian Diagnostics and was previously Biochemist and Unit Manager at Karolinska University Laboratory with research focusing on biomarkers for inflammation and infection.
Dr Erling Sundrehagen (71), who co-founded Gentian in 2001 and has held the CSO role since 2019, is moving into a new role as Consulting Founder and will initially devote his time to the development of NT-proBNP. In 2022, Gentian strengthened its R&D team which now consists of Dr Torsten Knüttel (VP R&D), Dr Tom Nilsen (Head of Product Development) and Dr Ingo Curdt (Head of Innovation and Research) who joined the company earlier this year.
In connection with the organizational changes, Dr Sundrehagen says: ” We now have a highly qualified technical team with best-in-class development capabilities and a track record of bringing industry-changing innovations to the market. I am confident that Gentian will continue to bring innovative diagnostics products to the market going forward.”
“We are delighted that Aleksandra Havelka, a highly qualified member of our team and a respected scientist, will take on this new role and further enhance her close collaboration with the R&D team. After decades of bringing diagnostic innovations to the market, our co-founder Erling Sundrehagen is pleased to move into a more consultative role and hand over more of the responsibility to the competent team that he has helped to form and develop. Erling will continue to contribute with his insights, focusing on NT-proBNP and the early phase of developing new products. With Aleksandra as CSO and the strengthening of our R&D team, Gentian is well-positioned to deliver on its growth ambitions,” says Hilja Ibert, CEO of Gentian Diagnostics.
The announced changes will take effect from 1 January 2023.
This information is subject to the disclosure requirements pursuant to the market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading Act.
For further information, please contact:
Hilja Ibert, CEO
hilja.ibert@gentian.no
+47 919 05 242 (mobile)
Njaal Kind, CFO and COO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
To see the announcement follow this link: https://newsweb.oslobors.no/message/578196